Keywords = Sorafenib
| Number of Articles: 19 | ||||
| 1 | Disturbing intracellular replication of Helicobacter Pylori by Sorafenib treatment in-vitro | |||
| Articles in Press, Accepted Manuscript , Available Online from 27 December 2021 | ||||
| Tamer Roshdy; shimaa Ahmed Saleh; Nasser Abbas; Khalid Bassiouny; Hany Khalil | ||||
| 2 | Chemotherapeutic Effect of Stigmasterol in Sorafenib Treated Breast Cancer Cell Lines via Modulation of NF-κB and ERK Signaling Pathways | |||
| Volume 67, Issue 3, March 2024, Page 227-234 | ||||
| asmaa elshamy; Gamal Omran; Mohammad Abd-Alhaseeb; MAHA HOUSSEN | ||||
| 3 | Outcomes of hepatocellular carcinoma among patients receiving systemic therapy | |||
| Volume 35, Issue 1, January 2024, Page 44-48 | ||||
| Yara Mohamed Salah; Hala Ibrahem Mohamed; Nady Mahmoud Semeda | ||||
| 4 | Antitumor Effect of Esculetin on Sorafenib -Treated Human Hepatocellular Carcinoma Cell Lines Via Suppression of VEGF-EGFR/RAS/ERK/NF-κB Pathway and Modulation of pI3K/ P38 Axis Crosstalk | |||
| Volume 66, Issue 12, December 2023, Page 335-346 | ||||
| Islam Adel; mohamed A tantawy; Ahmad Salahuddin; MAHA HOUSSEN | ||||
| 5 | Biomolecular evaluation of apoptosis, cell cycle, oxidative stress, and limiting enzymes of the glycolytic pathway in hepatocellular carcinoma cell line HepG2 treated with crude snake venom with or without sorafenib | |||
| Volume 9, Issue 3, September 2023, Page 115-137 | ||||
| Maha Y. Abdel Al Shakour; Emad M. Elzayat; Khalid M. Mahmoud; Mamdouh I. Nassar; Abdel Hamid Z. Abdel-Hamid | ||||
| 6 | Impact of Prognostic Nutritional Index and Systemic Immune-Inflammation Index on the Clinical Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib | |||
| Volume 29, Issue 2, March 2023, Page 650-663 | ||||
| Ahmad Barakat Waley; Rasha Haggag; Amir Abd-elhameed Ahmed Barakat; Hanaa Ahmed Rashied; Ahmed Abdul-Saboor; Marwa Mohammed Esawy; Yasser Orban; Adel Bakry | ||||
| 7 | Adherence to Sorafenib Therapy Is Not Affected by Treatment-Related Side Effects or Demographic Characteristics of Iraqi Patients with Hepatocellular Carcinoma | |||
| Volume 90, Issue 1, January 2023, Page 1690-1679 | ||||
| Tuqa Haitham Qasim; Mohammed Abdul-Hassan Jabarah AL-Zobaidy; Mazin Jody | ||||
| 8 | Anticancer effect of Sorafenib-loaded iron oxide nanoparticles and bee venom on some genes expression in hepatocellular carcinoma | |||
| Volume 65, Issue 132, December 2022, Page 1477-1487 | ||||
| Rana A. A. Nagy; Heba K.A. Elhakim; mona hassan mohamed; Mie afify; Mohamed D.E. Abd El-Maksoud; abd el razik farrag mohamed; Doaa S. R. Khafaga; May M. Eid | ||||
| 9 | Alginate/CaCO3 Hybrid Loaded With Sorafenib Tosylate and Gold Hexagons: A Model for Efficient Dual (Chemo-Radio) Treatment of HepG2 Cells | |||
| Volume 65, Issue 5, May 2022, Page 723-735 | ||||
| Firas A. Sukkar; Medhat W. Shafaa; Mohamed S El-Nagdy; Wael M. Darwish | ||||
| 10 | Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Sorafenib versus Radiotherapy | |||
| Volume 10, Issue 1, January 2022, Page 34-43 | ||||
| 11 | Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study | |||
| Volume 17, Issue 1, 2021, Page 59-68 | ||||
| Radi Ali; Hala Galal El-Tantawi; Mohammed El-Sayed Rizk; Sabry Ali El-Naggar; Alaa Elmetwalli; Afrah Fatthi Salama | ||||
| 12 | Effect of Sorafenib on Liver Biochemistry Prior to Vitamin B17 Coadministration in Ehrlich Ascites Carcinoma Mice Model: Preliminary Phase Study | |||
| Volume 17, Issue 1, 2021, Page 40-49 | ||||
| Hebatalla M. Nasser; Sabry Ali El-Naggar; Mohammed El-Sayed Rizk El-Sayed Rizk; Alaa Elmetwalli; Afrah Fatthi Salama | ||||
| 13 | Antioxidant and Cytotoxicity Potential of Piperine and Sorafenib combination in human MDA-MB-231 Breast Cancer cells | |||
| Volume 17, Issue 1, 2021, Page 108-116 | ||||
| Hany Mohany; Mohammad A. Mahmoud; Ashraf A. El-Shehawy; Mohamed Gaber; Alaa Elmetwalli; Afrah F. Salama; Tarek El Sewedy | ||||
| 14 | Amygdalin Enhances the Antitumor Effect of Sorafenib | |||
| Volume 13, Issue 2, December 2021, Page 61-68 | ||||
| Alaa Elmetwalli; Aya M. Abdel Khalek; Sabry A. El-Naggar; Mohammed A. El-Magd; Afrah F. Salama | ||||
| 15 | Disturbing intracellular replication of Helicobacter pylori by sorafenib treatment in-vitro | |||
| Volume 17, Issue 1, 2021, Page 285-295 | ||||
| Tamer Mohammed Roshdy; Shimaa A. Saleh; Nasser H. Abass; Khalid Bassiouny; Hany Khalil | ||||
| 16 | Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients | |||
| Volume 4, Issue 2, December 2020, Page 224-236 | ||||
| Noha El Baghdady; Lamia Elwakeel; Mahmoud Ellithy; Nawal Hussein; Sara Shahin; Abdel Rahman El Naggar | ||||
| 17 | Possible role of angiogenesis suppression in rats model of non alcoholic fatty liver disease | |||
| Volume 39, Issue 2, December 2019, Page 173-190 | ||||
| Dalia Mohammed Abdel ghaffar Rezk; mohammed el mahdy sarhan; hanaa ahmed abdel moniem; amr medhat abbas; mohammad eldosoky salama | ||||
| 18 | Downregulation of miR-23a and miR-24 in human hepatocellular carcinoma cells by Sorafenib via transforming growth factor-beta 1 in a SMAD dependent manner | |||
| Volume 5, Issue 3, September 2019, Page 340-351 | ||||
| Eman G. Ayad; Mohga S. Abdulla; Hayat M. Sharada; Abdel Hady A. Abdel Wahab; Abeer M. Ashmawy | ||||
| 19 | CYTOTOXICITY OF SORAFENIB IN HUMAN HEPATOCELLULAR CARCINOMA CELLS | |||
| Volume 51, Issue 1, March 2015, Page 31-40 | ||||
| Mai Abd El-Mageed | ||||
| | ||||
View on SCiNiTO